Gene therapy for viral hepatitis

Bibliography

• WHO: Hepatitis B vaccines. Wkly Epidemiol. Rec. (2004) 79:255-263.
   PubMedGoogle Scholar
• MCHUTCHISON JG, BACON BR: Chronic hepatitis C: an age wave of disease burden. Am. J. Manag. Care (2005) 11(10 Suppl.):S286-S295; quiz S307-S211.
   PubMed Web of Science ®Google Scholar
• JANSSEN HL, VAN ZONNEVELD M, SENTURK H et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 365(9454):123-129.
   PubMed Web of Science ®Google Scholar
• FRIED MW, SHIFFMAN ML, REDDY KR et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. (2002) 347(13):975-982.
   PubMed Web of Science ®Google Scholar
• LOCARNINI S: Molecular virology of hepatitis B virus. Semin. Liver Dis. (2004) 24(Suppl. 1):3-10.
   PubMed Web of Science ®Google Scholar
• GRIPON P, RUMIN S, URBAN S et al.: Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. USA (2002) 99(24):15655-15660.
   PubMed Web of Science ®Google Scholar
• ENGELKE M, MILLS K, SEITZ S et al.: Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology (2006) 43(4):750-760.
   PubMed Web of Science ®Google Scholar
• BARKER LF, MAYNARD JE, PURCELL RH et al.: Viral hepatitis, type B, in experimental animals. Am. J. Med. Sci. (1975) 270(1):189-195.
   PubMed Web of Science ®Google Scholar
• TAKEHARA T, SUZUKI T, OHKAWA K et al.: Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication. J. Hepatol. (2006) 44(2):267-274.
   PubMed Web of Science ®Google Scholar
• REN S, NASSAL M: Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors. J. Virol. (2001) 75(3):1104-1116.
   PubMed Web of Science ®Google Scholar
• KETZINEL-GILAD M, ZAUBERMAN A, NUSSBAUM O et al.: The use of the hydrodynamic HBV animal model to study HBV biology and anti-viral therapy. Hepatol. Res. (2006) 34(4):228-237.
   PubMed Web of Science ®Google Scholar
• DANDRI M, BURDA MR, TOROK E et al.: Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology (2001) 33(4):981-988.
   PubMed Web of Science ®Google Scholar
• TENNANT BC, GERIN JL: The woodchuck model of hepatitis B virus infection. ILAR J. (2001) 42(2):89-102.
   PubMedGoogle Scholar
• TENNANT BC, TOSHKOV IA, PEEK SF et al.: Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology (2004) 127(5 Suppl. 1):S283-S293.
   PubMed Web of Science ®Google Scholar
• SCHULTZ U, GRGACIC E, NASSAL M: Duck hepatitis B virus: an invaluable model system for HBV infection. Adv. Virus Res. (2004) 63:1-70.
   PubMed Web of Science ®Google Scholar
• BARTENSCHLAGER R, LOHMANN V: Replication of the hepatitis C virus. Baillieres Best Pract. Res. Clin. Gastroenterol. (2000) 14(2):241-254.
   PubMed Web of Science ®Google Scholar
• LOHMANN V, KORNER F, KOCH J et al.: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 285(5424):110-113.
   PubMed Web of Science ®Google Scholar
• BLIGHT KJ, KOLYKHALOV AA, RICE CM: Efficient initiation of HCV RNA replication in cell culture. Science (2000) 290(5498):1972-1974.
   PubMed Web of Science ®Google Scholar
• PIETSCHMANN T, LOHMANN V, KAUL A et al.: Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J. Virol. (2002) 76(8):4008-4021.
   PubMed Web of Science ®Google Scholar
• BLIGHT KJ, MCKEATING JA, RICE CM: Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. (2002) 76(24):13001-13014.
   PubMed Web of Science ®Google Scholar
• PIETSCHMANN T, BARTENSCHLAGER R: The hepatitis C virus replicon system and its application to molecular studies. Curr. Opin. Drug Discov. Devel. (2001) 4(5):657-664.
   PubMedGoogle Scholar
• BARTENSCHLAGER R: Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture. Curr. Opin. Microbiol. (2006) 9(4):416-422.
   PubMed Web of Science ®Google Scholar
• WAKITA T, PIETSCHMANN T, KATO T et al.: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. (2005) 11(7):791-796.
   PubMed Web of Science ®Google Scholar
• BUKH J: A critical role for the chimpanzee model in the study of hepatitis C. Hepatology (2004) 39(6):1469-1475.
   PubMed Web of Science ®Google Scholar
• MEULEMAN P, LIBBRECHT L, DE VOS R et al.: Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology (2005) 41(4):847-856.
   PubMed Web of Science ®Google Scholar
• MAEDA N, WATANABE M, OKAMOTO S et al.: Hepatitis C virus infection in human liver tissue engrafted in mice with an infectious molecular clone. Liver Int. (2004) 24(3):259-267.
   PubMed Web of Science ®Google Scholar
• BEAMES B, CHAVEZ D, LANFORD RE: GB virus B as a model for hepatitis C virus. ILAR J. (2001) 42(2):152-160.
   PubMedGoogle Scholar
• LIU F, TYAGI P: Naked DNA for liver gene transfer. Adv. Genet. (2005) 54:43-64.
   PubMed Web of Science ®Google Scholar
• WELLS DJ: Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther. (2004) 11(18):1363-1369.
   PubMed Web of Science ®Google Scholar
• BANERJEE R: Liposomes: applications in medicine. J. Biomater. Appl. (2001) 16(1):3-21.
   PubMed Web of Science ®Google Scholar
• ZHENG SJ, ZHONG S, ZHANG JJ et al.: Distribution and anti-HBV effects of antisense oligodeoxynucleotides conjugated to galactosylated poly-L-lysine. World J. Gastroenterol. (2003) 9(6):1251-1255.
   PubMed Web of Science ®Google Scholar
• LUNGWITZ U, BREUNIG M, BLUNK T, GOPFERICH A: Polyethylenimine-based non-viral gene delivery systems. Eur. J. Pharm. Biopharm. (2005) 60(2):247-266.
   PubMed Web of Science ®Google Scholar
• LEE MK, CHUN SK, CHOI WJ et al.: The use of chitosan as a condensing agent to enhance emulsion-mediated gene transfer. Biomaterials (2005) 26(14):2147-2156.
   PubMed Web of Science ®Google Scholar
• WANG SN, DENG YH, XU H et al.: Synthesis of a novel galactosylated lipid and its application to the hepatocyte-selective targeting of liposomal doxorubicin. Eur. J. Pharm. Biopharm. (2006) 62(1):32-38.
   PubMed Web of Science ®Google Scholar
• KIM EM, JEONG HJ, PARK IK et al.: Asialoglycoprotein receptor targeted gene delivery using galactosylated polyethylenimine-graft-poly(ethylene glycol): in vitro and in vivo studies. J. Control. Release (2005) 108(2-3):557-567.
   PubMed Web of Science ®Google Scholar
• MCCARTY DM, YOUNG SM JR, SAMULSKI RJ: Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. (2004) 38:819-845.
   PubMed Web of Science ®Google Scholar
• GRIMM D, KAY MA: From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. (2003) 3(4):281-304.
   PubMedGoogle Scholar
• BERRAONDO P, CRETTAZ J, OCHOA L et al.: Intrahepatic injection of recombinant adeno-associated virus serotype 2 overcomes gender-related differences in liver transduction. Hum. Gene Ther. (2006) 17(6):601-610.
   PubMed Web of Science ®Google Scholar
• WAGNER JA, MESSNER AH, MORAN ML et al.: Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope (1999) 109(2 Pt 1):266-274.
   PubMed Web of Science ®Google Scholar
• MANDEL RJ, BURGER C: Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr. Opin. Mol. Ther. (2004) 6(5):482-490.
   PubMed Web of Science ®Google Scholar
• WARRINGTON KH JR, HERZOG RW: Treatment of human disease by adeno-associated viral gene transfer. Hum. Genet. (2006) 119(6):571-603.
   PubMed Web of Science ®Google Scholar
• MANNO CS, PIERCE GF, ARRUDA VR et al.: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. (2006) 12(3):342-347.
   PubMed Web of Science ®Google Scholar
• GHOSH SS, GOPINATH P, RAMESH A: Adenoviral vectors: a promising tool for gene therapy. Appl. Biochem. Biotechnol. (2006) 133(1):9-29.
   PubMed Web of Science ®Google Scholar
• YOUNG LS, SEARLE PF, ONION D, MAUTNER V: Viral gene therapy strategies: from basic science to clinical application. J. Pathol. (2006) 208(2):299-318.
   PubMed Web of Science ®Google Scholar
• WARREN RS, KIRN DH: Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond. Surg. Oncol. Clin. North Am. (2002) 11(3):571-588, vi.
   PubMedGoogle Scholar
• CHAISOMCHIT S, TYRRELL DL, CHANG LJ: Development of replicative and nonreplicative hepatitis B virus vectors. Gene Ther. (1997) 4(12):1330-1340.
   PubMed Web of Science ®Google Scholar
• UNTERGASSER A, PROTZER U: Hepatitis B virus-based vectors allow the elimination of viral gene expression and the insertion of foreign promoters. Hum. Gene Ther. (2004) 15(2):203-210.
   PubMed Web of Science ®Google Scholar
• YOO J, RHO J, LEE D, SHIN S, JUNG G: Hepatitis B virus vector carries a foreign gene into liver cells in vitro. Virus Genes (2002) 24(3):215-224.
   PubMed Web of Science ®Google Scholar
• PASEK M, GOTO T, GILBERT W et al.: Hepatitis B virus genes and their expression in E. coli. Nature (1979) 282(5739):575-579.
   PubMed Web of Science ®Google Scholar
• COOPER A, SHAUL Y: Recombinant viral capsids as an efficient vehicle of oligonucleotide delivery into cells. Biochem. Biophys. Res. Commun. (2005) 327(4):1094-1099.
   PubMed Web of Science ®Google Scholar
• YU D, FUKUDA T, TUOYA et al.: Engineered bio-nanocapsules, the selective vector for drug delivery system. IUBMB Life (2006) 58(1):1-6.
   PubMed Web of Science ®Google Scholar
• MIYATAKE S: Gene therapy using tissue-specific replication competent HSV. Hum. Cell (2002) 15(3):130-137.
   PubMedGoogle Scholar
• GHOSH S, PARVEZ MK, BANERJEE K, SARIN SK, HASNAIN SE: Baculovirus as mammalian cell expression vector for gene therapy: an emerging strategy. Mol. Ther. (2002) 6(1):5-11.
   PubMed Web of Science ®Google Scholar
• PAROUCHEV A, NGUYEN TH, DAGHER I et al.: Efficient ex vivo gene transfer into non-human primate hepatocytes using HIV-1 derived lentiviral vectors. J. Hepatol. (2006) 45(1):99-107.
   PubMed Web of Science ®Google Scholar
• GRIMM D, KAY MA: Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther. (2006) 13(6):563-575.
   PubMed Web of Science ®Google Scholar
• MCCAFFREY AP, NAKAI H, PANDEY K et al.: Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. (2003) 21(6):639-644.
   PubMed Web of Science ®Google Scholar
• KLEIN C, BOCK CT, WEDEMEYER H et al.: Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology (2003) 125(1):9-18.
   PubMed Web of Science ®Google Scholar
• UPRICHARD SL, BOYD B, ALTHAGE A, CHISARI FV: Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc. Natl. Acad. Sci. USA (2005) 102(3):773-778.
   PubMed Web of Science ®Google Scholar
• GRIMM D, STREETZ KL, JOPLING CL et al.: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 441(7092):537-541.
   PubMed Web of Science ®Google Scholar
• BAGASRA O: RNAi as an antiviral therapy. Expert Opin. Biol. Ther. (2005) 5(11):1463-1474.
   PubMed Web of Science ®Google Scholar
• WILSON JA, RICHARDSON CD: Future promise of siRNA and other nucleic acid based therapeutics for the treatment of chronic HCV. Infect. Disord. Drug Targets (2006) 6(1):43-56.
   PubMedGoogle Scholar
• WILSON JA, RICHARDSON CD: Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J. Virol. (2005) 79(11):7050-7058.
   PubMed Web of Science ®Google Scholar
• ZHANG J, YAMADA O, SAKAMOTO T et al.: Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus. Virology (2004) 320(1):135-143.
   PubMed Web of Science ®Google Scholar
• MCCAFFREY AP, MEUSE L, PHAM TT et al.: RNA interference in adult mice. Nature (2002) 418(6893):38-39.
   PubMed Web of Science ®Google Scholar
• COUTO LB, PARKER AE, HANIFF G et al.: RNAi-based therapy for the treatment of HCV. 9th Annual Meeting of The American Society of Gene Therapy. Baltimore, MD, USA (31 May – 4 June 2006).
   Google Scholar
• HASELOFF J, GERLACH WL: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature (1988) 334(6183):585-591.
   PubMed Web of Science ®Google Scholar
• XU R, CAI K, ZHENG D et al.: Molecular therapeutics of HBV. Curr. Gene Ther. (2003) 3(4):341-355.
   PubMedGoogle Scholar
• NASH KL, ALEXANDER GJ, LEVER AM: Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes. J. Viral Hepat. (2005) 12(4):346-356.
   PubMed Web of Science ®Google Scholar
• MORRISSEY DV, LEE PA, JOHNSON DA et al.: Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA. J. Viral Hepat. (2002) 9(6):411-418.
   PubMed Web of Science ®Google Scholar
• PAN WH, XIN P, MORREY JD, CLAWSON GA: A self-processing ribozyme cassette: utility against human papillomavirus 11 E6/E7 mRNA and hepatitis B virus. Mol. Ther. (2004) 9(4):596-606.
   PubMed Web of Science ®Google Scholar
• ROMERO-LOPEZ C, SANCHEZ-LUQUE FJ, BERZAL-HERRANZ A: Targets and tools: recent advances in the development of anti-HCV nucleic acids. Infect. Disord. Drug Targets (2006) 6(2):121-145.
   PubMedGoogle Scholar
• MACEJAK DG, JENSEN KL, JAMISON SF et al.: Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology (2000) 31(3):769-776.
   PubMed Web of Science ®Google Scholar
• SCHUBERT S, KURRECK J: Oligonucleotide-based antiviral strategies. Handb. Exp. Pharmacol. (2006) (173):261-287.
   PubMedGoogle Scholar
• ROBACZEWSKA M, GUERRET S, REMY JS et al.: Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver. Gene Ther. (2001) 8(11):874-881.
   PubMed Web of Science ®Google Scholar
• OFFENSPERGER WB, OFFENSPERGER S, WALTER E et al.: In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J. (1993) 12(3):1257-1262.
   PubMed Web of Science ®Google Scholar
• ZHANG H, HANECAK R, BROWN-DRIVER V et al.: Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob. Agents Chemother. (1999) 43(2):347-353.
   PubMed Web of Science ®Google Scholar
• MCCAFFREY AP, MEUSE L, KARIMI M, CONTAG CH, KAY MA: A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology (2003) 38(2):503-508.
   PubMed Web of Science ®Google Scholar
• MCHUTCHISON JG, PATEL K, POCKROS P et al.: A Phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J. Hepatol. (2006) 44(1):88-96.
   PubMed Web of Science ®Google Scholar
• SCAGLIONI P, MELEGARI M, TAKAHASHI M, CHOWDHURY JR, WANDS J: Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology (1996) 24(5):1010-1017.
   PubMed Web of Science ®Google Scholar
• BRUSS V: A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation. J. Virol. (1997) 71(12):9350-9357.
   PubMed Web of Science ®Google Scholar
• MELEGARI M, SCAGLIONI PP, WANDS JR: Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. J. Virol. (1998) 72(3):1737-1743.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO M, HAYASHI N, TAKEHARA T et al.: Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells. Hepatology (1999) 30(1):300-307.
   PubMed Web of Science ®Google Scholar
• JIN YH, KWON MH, KIM K et al.: An intracellular antibody can suppress tumorigenicity in hepatitis B virus X-expressing cells. Cancer Immunol. Immunother. (2006) 55(5):569-578.
   PubMed Web of Science ®Google Scholar
• TOMAI E, BUTZ K, LOHREY C et al.: Peptide aptamer-mediated inhibition of target proteins by sequestration into aggresomes. J. Biol. Chem. (2006) 281(30):21345-21352.
   PubMed Web of Science ®Google Scholar
• UMEHARA T, FUKUDA K, NISHIKAWA F et al.: Rational design of dual-functional aptamers that inhibit the protease and helicase activities of HCV NS3. J. Biochem. (Tokyo) (2005) 137(3):339-347.
   PubMed Web of Science ®Google Scholar
• REHERMANN B, NASCIMBENI M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. (2005) 5(3):215-229.
   PubMed Web of Science ®Google Scholar
• MATSKEVICH AA, STRAYER DS: Exploiting hepatitis C virus activation of NFkappaB to deliver HCV-responsive expression of interferons alpha and gamma. Gene Ther. (2003) 10(22):1861-1873.
   PubMed Web of Science ®Google Scholar
• MATSKEVICH AA, CORDELIER P, STRAYER DS: Conditional expression of IFN-alpha and IFN-gamma activated by HBV as genetic therapy for hepatitis B. J. Interferon Cytokine Res. (2003) 23(12):709-721.
   PubMed Web of Science ®Google Scholar
• DUMORTIER J, SCHONIG K, OBERWINKLER H et al.: Liver-specific expression of interferon gamma following adenoviral gene transfer controls hepatitis B virus replication in mice. Gene Ther. (2005) 12(8):668-677.
   PubMed Web of Science ®Google Scholar
• SALUCCI V, LU M, AURISICCHIO L et al.: Expression of a new woodchuck IFN-alpha gene by a helper-dependent adenoviral vector in woodchuck hepatitis virus-infected primary hepatocytes. J. Interferon Cytokine Res. (2002) 22(10):1027-1034.
   PubMed Web of Science ®Google Scholar
• FIEDLER M, RODICKER F, SALUCCI V et al.: Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-alpha) and IFN-gamma: IFN-alpha but not IFN-gamma reduces woodchuck hepatitis virus replication in chronic infection in vivo. J. Virol. (2004) 78(18):10111-10121.
   PubMed Web of Science ®Google Scholar
• BERRAONDO P, OCHOA L, CRETTAZ J et al.: IFN-alpha gene therapy for woodchuck hepatitis with adeno-associated virus: differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes. Mol. Ther. (2005) 12(1):68-76.
   PubMed Web of Science ®Google Scholar
• SUZUKI K, AOKI K, OHNAMI S et al.: Adenovirus-mediated gene transfer of interferon alpha inhibits hepatitis C virus replication in hepatocytes. Biochem. Biophys. Res. Commun. (2003) 307(4):814-819.
   PubMed Web of Science ®Google Scholar
• AURISICCHIO L, DE TOMASSI A, LA MONICA N et al.: Regulated and liver-specific tamarin alpha interferon gene delivery by a helper-dependent adenoviral vector. J. Virol. (2005) 79(11):6772-6780.
   PubMed Web of Science ®Google Scholar
• SHIN EC, PROTZER U, UNTERGASSER A et al.: Liver-directed gamma interferon gene delivery in chronic hepatitis C. J. Virol. (2005) 79(21):13412-13420.
   PubMed Web of Science ®Google Scholar
• MICHEL ML, MANCINI-BOURGINE M: Therapeutic vaccination against chronic hepatitis B virus infection. J. Clin. Virol. (2005) 34(Suppl. 1):S108-S114.
   PubMedGoogle Scholar
• SHIINA M, REHERMANN B: Hepatitis C vaccines: inducing and challenging memory T cells. Hepatology (2006) 43(6):1395-1398.
   PubMedGoogle Scholar
• PAOLETTI E, LIPINSKAS BR, SAMSONOFF C, MERCER S, PANICALI D: Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc. Natl. Acad. Sci. USA (1984) 81(1):193-197.
   PubMed Web of Science ®Google Scholar
• DAVIS HL, MICHEL ML, WHALEN RG: DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet. (1993) 2(11):1847-1851.
   PubMed Web of Science ®Google Scholar
• TACKET CO, ROY MJ, WIDERA G et al.: Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine (1999) 17(22):2826-2829.
   PubMed Web of Science ®Google Scholar
• MANCINI-BOURGINE M, FONTAINE H, BRECHOT C, POL S, MICHEL ML: Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine (2006) 24(21):4482-4489.
   PubMed Web of Science ®Google Scholar
• MANCINI-BOURGINE M, FONTAINE H, SCOTT-ALGARA D et al.: Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology (2004) 40(4):874-882.
   PubMed Web of Science ®Google Scholar
• YANG SH, LEE CG, PARK SH et al.: Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther. (2006) 13(14):1110-1117.
   PubMed Web of Science ®Google Scholar
• MAJOR ME, VITVITSKI L, MINK MA et al.: DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J. Virol. (1995) 69(9):5798-5805.
   PubMed Web of Science ®Google Scholar
• MAKIMURA M, MIYAKE S, AKINO N et al.: Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine (1996) 14(1):28-36.
   PubMed Web of Science ®Google Scholar
• ROLLIER C, DEPLA E, DREXHAGE JA et al.: Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J. Virol. (2004) 78(1):187-196.
   PubMed Web of Science ®Google Scholar
• ROLLIER C, VERSCHOOR EJ, PARANHOS-BACCALA G et al.: Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting. J. Infect. Dis. (2005) 192(5):920-929.
   PubMed Web of Science ®Google Scholar
• FOLGORI A, SPADA E, PEZZANERA M et al.: Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut (2006) 55(7):1012-1019.
   PubMed Web of Science ®Google Scholar
• FOLGORI A, CAPONE S, RUGGERI L et al.: A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. (2006) 12(2):190-197.
   PubMed Web of Science ®Google Scholar
• TRIYATNI M, JILBERT AR, QIAO M, MILLER DS, BURRELL CJ: Protective efficacy of DNA vaccines against duck hepatitis B virus infection. J. Virol. (1998) 72(1):84-94.
   PubMed Web of Science ®Google Scholar
• MILLER DS, KOTLARSKI I, JILBERT AR: DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner. Virology (2006) 351(1):159-169.
   PubMed Web of Science ®Google Scholar
• ROLLIER C, CHAROLLOIS C, JAMARD C, TREPO C, COVA L: Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection. J. Virol. (2000) 74(10):4908-4911.
   PubMed Web of Science ®Google Scholar
• ROLLIER C, CHAROLLOIS C, JAMARD C, TREPO C, COVA L: Early life humoral response of ducks to DNA immunization against hepadnavirus large envelope protein. Vaccine (2000) 18(27):3091-3096.
   PubMed Web of Science ®Google Scholar
• ROLLIER C, SUNYACH C, BARRAUD L et al.: Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology (1999) 116(3):658-665.
   PubMed Web of Science ®Google Scholar
• LE GUERHIER F, THERMET A, GUERRET S et al.: Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. J. Hepatol. (2003) 38(3):328-334.
   PubMed Web of Science ®Google Scholar
• LU M, HILKEN G, KRUPPENBACHER J et al.: Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J. Virol. (1999) 73(1):281-289.
   PubMed Web of Science ®Google Scholar
• SIEGEL F, LU M, ROGGENDORF M: Coadministration of gamma interferon with DNA vaccine expressing woodchuck hepatitis virus (WHV) core antigen enhances the specific immune response and protects against WHV infection. J. Virol. (2001) 75(11):5036-5042.
   PubMed Web of Science ®Google Scholar
• GARCIA-NAVARRO R, BLANCO-URGOITI B, BERRAONDO P et al.: Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12. J. Virol. (2001) 75(19):9068-9076.
   PubMed Web of Science ®Google Scholar
• PANCHOLI P, LEE DH, LIU Q et al.: DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology (2001) 33(2):448-454.
   PubMed Web of Science ®Google Scholar
• SHATA MT, PFAHLER W, BROTMAN B et al.: Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load. J. Med. Pr.imatol. (2006) 35(3):165-171.
   Google Scholar
• PRINCE AM, WHALEN R, BROTMAN B: Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine (1997) 15(8):916-919.
   Google Scholar
• SALLBERG M, HUGHES J, JAVADIAN A et al.: Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum. Gene Ther. (1998) 9(12):1719-1729.
   Google Scholar
• ABRAHAM JD, HIMOUDI N, KIEN F et al.: Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine (2004) 22(29-30):3917-3928.
   Google Scholar
• PANCHOLI P, LIU Q, TRICOCHE N et al.: DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. J. Infect. Dis. (2000) 182(1):18-27.
   Google Scholar
• WUEST T, BOTH GW, PRINCE AM, HOFMANN C, LOSER P: Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine (2004) 22(21-22):2717-2721.
   Google Scholar
• GORDON EJ, BHAT R, LIU Q et al.: Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations. J. Infect. Dis. (2000) 181(1):42-50.
   Google Scholar
• MAJID AM, EZELLE H, SHAH S, BARBER GN: Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. J. Virol. (2006) 80(14):6993-7008.
   Google Scholar
• FATTORI E, ZAMPAGLIONE I, ARCURI M et al.: Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes. Gene Ther. (2006) 13(14):1088-1096.
   Google Scholar
• CAPONE S, MEOLA A, ERCOLE BB et al.: A novel adenovirus Type 6(Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J. Virol. (2006) 80(4):1688-1699.
   Google Scholar
• FORNS X, PAYETTE PJ, MA X et al.: Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology (2000) 32(3):618-625.
   Google Scholar